A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
NCT ID: NCT00778700
Last Updated: 2022-02-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
199 participants
INTERVENTIONAL
2008-10-28
2009-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
NCT00617994
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
NCT00820950
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
NCT03850483
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
NCT05593432
Topical Ruxolitinib Lichen Planus
NCT03697460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vehicle Cream
Vehicle cream, applied topically, once daily from Day 1 to Week 12.
Placebo Cream
Cream with no active drug
Ruxolitinib Phosphate 0.5% Cream
Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
Ruxolitinib Phosphate
Ruxolitinib phosphate cream
Ruxolitinib Phosphate 1.0% Cream
Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
Ruxolitinib Phosphate
Ruxolitinib phosphate cream
Ruxolitinib Phosphate 1.5% Cream
Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.
Ruxolitinib Phosphate
Ruxolitinib phosphate cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo Cream
Cream with no active drug
Ruxolitinib Phosphate
Ruxolitinib phosphate cream
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Systemic therapy for their psoriasis
* Pustular psoriasis or erythroderma
* Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication
* Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis
* Receiving systemic triazole antifungals except fluconazole
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica Luchi, M.D.
Role: STUDY_DIRECTOR
Incyte Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hot Springs, Arkansas, United States
Los Angeles, California, United States
San Diego, California, United States
Santa Monica, California, United States
Vallejo, California, United States
New Haven, Connecticut, United States
Miami, Florida, United States
Ormond Beach, Florida, United States
Naperville, Illinois, United States
Wheaton, Illinois, United States
Evansville, Indiana, United States
South Bend, Indiana, United States
Boston, Massachusetts, United States
Clinton Township, Michigan, United States
Fridley, Minnesota, United States
St Louis, Missouri, United States
Albuquerque, New Mexico, United States
Rochester, New York, United States
Norman, Oklahoma, United States
Simpsonville, South Carolina, United States
Austin, Texas, United States
College Station, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Norfolk, Virginia, United States
Walla Walla, Washington, United States
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB 18424-203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.